I. INTRODUCTION

Presence of hypertension at a young age is associated with a higher risk of cardiovascular events in middle age. It contributes to an earlier onset of coronary heart disease, transient ischemic attacks, stroke & heart failure. Recognizing secondary causes of hypertension is potentially beneficial, as this might direct specific treatment strategies and potentially cure high blood pressure in young patients.

Chest pain in young adults is not rare. This symptom, however, is frequently atypical in its relationship to exertion and its duration, and after a thorough evaluation, it is often found to be benign in nature—for example, related to chest wall tenderness, costochondritis, hyperventilation, anxiety, mitral valve prolapses or a pulmonary disorder. In other cases, when the chest pain is unrelated to exertion, coronary or oesophageal spasms are other possibilities.

In young patients who present with chest pain, a detailed history should be taken with ischemic cardiac pain in mind before such a symptom is dismissed as benign and noncardiac. If the history is consistent with myocardial ischemia, exercise testing and possibly coronary angiography are indicated to rule out unusual and potentially correctable cardiac abnormalities.

II. CASE REPORT

The following case report describes a young woman with Chest pain & Hypertension.

30-year-old lady was admitted to the medical assessment unit with severe sudden onset left sided chest pain, radiating to the left arm and jaw which lasted for one hour and was associated with palpitation and sweating. She had history of similar pain for the last one week with minor frequency.

PMH: Hypertension.

Drug history: None.

Social history: Non-smoker & non-ETOH.

Family History: There is a family history of SDHB gene mutation - father died of metastatic Paraganglioma. Sister has had Paraganglioma removed. She has (according to her sister) never been checked for SHDB mutation.


Troponin I: 419 ng/L and 438 ng/L (ref 0 -16). Her Renal, Thyroid, Clotting screen including D Dimers were normal.

Was started on Acute Coronary Syndrome protocol & transferred to CCU, was prescribed Beta blocker but in view of strong family history of Pheochromocytoma, Beta blocker was not dispensed.

CT both adrenals: Adrenal glands appear normal in size and appearance with no focal lesion or nodularity identified.
Fig. 1. ECG: T wave inversion in anterior leads.

**Echocardiogram:** Severe hypokinesis of mid posterior wall, Normal LV size and wall thickness.
Normal LV systolic function, LVEF 60-70% visually, Normal RV size and function.
Mild mitral regurgitation.

**CT Coronary angiogram:** No plaque or stenosis on RCA, LMS & LAD.

**Plasma Metanephrines:**
P Metanephrine (seated): 629 pmol/L 0 – 509.
P Normetanephrine (seated): **15227** pmol/L 0 – 1179.
P 3-Methoxytyramine (seated) 229 pmol/L.

Fig. 2. NM Whole body FDG PET CT.
**NM Whole body FDG PET CT Report**

A malignant Paraganglioma at the level of the pelvic brim with a nodal metastasis at the aortic bifurcation and scattered skeletal metastatic deposits.

**Multidisciplinary Meeting Outcome**

The plan is oncological resection of the Paraganglioma (which will remove >95% of her visible disease) and then probably adjuvant therapy (with maybe MIBG or Lutetium or Temozolomide or other agents).

Her blood was sent for a gene test for SDHB for confirmation.

Start & titrate the Doxazosin up to a dose of 2mg BD if tolerated.

The aim is to achieve long term control over the next 10 years and beyond.

### III. DISCUSSION

Although Paraganglioma/ Pheochromocytoma is a rare cause of secondary hypertension, but due to strong family history of Paraganglioma in this case, it should be considered as a main differential diagnosis.

Pheochromocytoma crisis is an endocrine emergency associated with higher mortality. Recommended management includes the use of alpha blockade, which is strongly associated with survival of a crisis.

In patients with persistent hypotension, mechanical circulatory supportive therapy is strongly recommended. Surgical intervention is not advisable until patient is medically stabilized.

Paragangliomas are uncommon neuroendocrine tumours that originate from the extra-adrenal autonomic paraganglia, small organs consisting mainly of neuroendocrine cells that are derived from the embryonic neural crest and have the ability to secrete catecholamines.

Catecholamine-secreting paragangliomas often present clinically like pheochromocytomas with episodic headaches, hypertension, tachycardia and sweating. However, the distinction between pheochromocytoma and paraganglioma is important because of implications for associated neoplasms, risk for malignancy, and genetic testing.

Majority of paragangliomas appear to be sporadic. However, approximately one-third to one-half are associated with an inherited syndrome. Some hereditary paragangliomas, have been linked to pathogenic variants in the genes encoding different subunits of the succinate dehydrogenase (SDH) enzyme complex. In addition, susceptibility to pheochromocytomas and paragangliomas is an established component of four genetic syndromes, multiple endocrine neoplasia types 2A and 2B (MEN2), neurofibromatosis type 1 (NF1), von Hippel Lindau (VHL), and Carney-Stratakis dyad.

SDHB-related paragangliomas are usually extra-adrenal and present with an abdominal, pelvic, or thoracic catecholamine-secreting tumor. In general, it is associated with greater morbidity and mortality than other SDHx paraganglioma syndromes. SDHB pathogenic variant carriers develop disease at a relatively young age. SDHB pathogenic variants are also associated with a higher malignancy rate than other types of SDHx-associated familial paraganglioma syndromes.

The diagnosis of a secretory paraganglioma can usually be made by measurements of urinary and/or plasma fractionated metanephrines or catecholamines. Biochemical diagnosis should be followed by radiological evaluation (typically either CT or MRI of the abdomen and pelvis) to locate the tumor. If abdominal and pelvic CT or MRI is negative, the next step is cross-sectional imaging of the thorax/head and neck and/or radioisotope (functional) imaging using 18F-fludeoxyglucose (FDG) positron emission tomography (PET) or metaiodobenzylguanidine (MIBG).

Screening for germline pathogenic variants in SDH and other genes should be carried out in all patients with paraganglioma.

### IV. LEARNING POINTS

1) Thorough clinical history, including the family history is crucial in making the diagnosis which is especially vital in this case (i.e., family history of Pheo with SDHB mutation).

2) In the context of Hypertension when secondary cause of Pheochromocytoma is suspected, Beta blocker should be avoided as it precipitates the pheo crisis.

3) Role of Multidisciplinary meeting is very important in managing the complex cases, where different views help to make a unifying management plan.

4) If your clinical suspicion is high, do not be distracted by other features like in this case her chest pain was most likely a cardiac manifestation of Pheo rather than acute coronary syndrome.

5) You need to ask for further investigation, if initial tests results are negative in order to make a diagnosis, e.g., in her case, initial CT adrenal and CT angiogram were negative, but we asked for PET scan which confirmed metastatic Paraganglioma that can easily be missed.

6) Diagnosis of a sporadic paraganglioma or pheochromocytoma should lead to a full genetic workup of the patient and family if SDH mutations are found.

### REFERENCES